{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:17:12Z","timestamp":1790471832011,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jaip.2019.08.022","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T19:09:15Z","timestamp":1566932955000},"page":"498-506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis"],"prefix":"10.1016","volume":"8","author":[{"given":"Catherine R.","family":"Weiler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2019.08.022_bib1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib2","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.08.022_bib3","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.jaci.2010.08.035","article-title":"Mast cell activation syndrome: proposed diagnostic criteria","volume":"126","author":"Akin","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib4","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \"idiopathic\" anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib5","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1182\/blood-2016-09-731893","article-title":"2016 updated WHO classification and novel emerging treatment concepts","volume":"129","author":"Valent","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.25371","article-title":"Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management","volume":"94","author":"Pardanani","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib7","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2018.06.004","article-title":"Mast cell activation syndrome: importance of consensus criteria and call for research","volume":"142","author":"Valent","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jaci.2011.04.037","article-title":"Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations","volume":"128","author":"Hamilton","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","article-title":"Characterization of mast cell activation syndrome","volume":"353","author":"Afrin","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaip.2019.08.022_bib10","first-page":"477","article-title":"Mast cell activation syndrome","volume":"15","author":"Kramer","year":"2017","journal-title":"Skinmed"},{"key":"10.1016\/j.jaip.2019.08.022_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12016-015-8487-6","article-title":"Mast cell activation syndrome","volume":"54","author":"Frieri","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib12","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jaip.2018.03.002","article-title":"Generalized pruritus relieved by NSAIDs in the setting of mast cell activation syndrome","volume":"6","author":"Kesterson","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.08.022_bib13","first-page":"8920921","article-title":"Management of a parturient with mast cell activation syndrome: an anesthesiologist's experience","volume":"2018","author":"Kumaraswami","year":"2018","journal-title":"Case Rep Anesthesiol"},{"key":"10.1016\/j.jaip.2019.08.022_bib14","first-page":"212","article-title":"Nonhistaminergic idiopathic angioedema may be a presentation of mast cell activation syndrome","volume":"23","author":"Afrin","year":"2013","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib15","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2019.02.002","article-title":"Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management","volume":"7","author":"Castells","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.08.022_bib16","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jaip.2018.11.045","article-title":"Doctor, I think I am suffering from MCAS: differential diagnosis and separating facts from fiction","volume":"7","author":"Valent","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.08.022_bib17","series-title":"Never bet against occam: mast cell activation disease and the modern epidemics of chronic illness and medical complexity","author":"Afrin","year":"2016"},{"key":"10.1016\/j.jaip.2019.08.022_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3121\/cmr.2017.1379a","article-title":"Flushing disorders associated with gastrointestinal symptoms: part 1, neuroendocrine tumors, mast cell disorders and hyperbasophila","volume":"16","author":"Rastogi","year":"2018","journal-title":"Clin Med Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3121\/cmr.2017.1379b","article-title":"Flushing disorders associated with gastrointestinal symptoms: part 2, systemic miscellaneous conditions","volume":"16","author":"Rastogi","year":"2018","journal-title":"Clin Med Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaad.2016.12.031","article-title":"Etiologies and management of cutaneous flushing: nonmalignant causes","volume":"77","author":"Sadeghian","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2019.08.022_bib21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.12.032","article-title":"Etiologies and management of cutaneous flushing: malignant causes","volume":"77","author":"Sadeghian","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2019.08.022_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/j.1559-4572.2008.00050.x","article-title":"Mechanisms of flushing due to niacin and abolition of these effects","volume":"11","author":"Sood","year":"2009","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.jaip.2019.08.022_bib23","first-page":"1","article-title":"Chronic urticaria: following practice guidelines","volume":"23","author":"Westby","year":"2018","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.jaip.2019.08.022_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12016-017-8628-1","article-title":"Urticaria and angioedema: an update on classification and pathogenesis","volume":"54","author":"Radonjic-Hoesli","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib25","first-page":"1068","article-title":"Isolated angioedema: an overview of clinical features and etiology","volume":"17","author":"Nedelea","year":"2019","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.jaip.2019.08.022_bib26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.gtc.2012.06.008","article-title":"Diarrhea caused by circulating agents","volume":"41","author":"Fabian","year":"2012","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.jaip.2019.08.022_bib27","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.3748\/wjg.v13.i34.4649","article-title":"Watery diarrhea, hypokalemia and achlorhydria syndrome due to an adrenal pheochromocytoma","volume":"13","author":"Ikuta","year":"2007","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jaip.2019.08.022_bib28","first-page":"55","article-title":"Pancreatic polypeptide hyperplasia causing watery diarrhea syndrome: a case report","volume":"42","author":"Pasieka","year":"1999","journal-title":"Can J Surg"},{"key":"10.1016\/j.jaip.2019.08.022_bib29","first-page":"156","article-title":"Overview of chronic diarrhea caused by functional neuroendocrine neoplasms","volume":"10","author":"Jensen","year":"1999","journal-title":"Semin Gastrointest Dis"},{"key":"10.1016\/j.jaip.2019.08.022_bib30","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/BF02285194","article-title":"Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel","volume":"40","author":"Harris","year":"1995","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaip.2019.08.022_bib31","doi-asserted-by":"crossref","first-page":"361","DOI":"10.5694\/j.1326-5377.2007.tb01282.x","article-title":"Serotonin toxicity: a practical approach to diagnosis and treatment","volume":"187","author":"Isbister","year":"2007","journal-title":"Med J Aust"},{"key":"10.1016\/j.jaip.2019.08.022_bib32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2146\/ajhp060069","article-title":"Facial flushing associated with duloxetine use","volume":"64","author":"Ezzo","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jaip.2019.08.022_bib33","first-page":"897902","article-title":"Serotonin syndrome after sertraline overdose in a child: a case report","volume":"2013","author":"Grenha","year":"2013","journal-title":"Case Rep Pediatr"},{"key":"10.1016\/j.jaip.2019.08.022_bib34","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1345\/aph.1D352","article-title":"Serotonin syndrome with elevated paroxetine concentrations","volume":"38","author":"Velez","year":"2004","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jaip.2019.08.022_bib35","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s10620-010-1560-3","article-title":"Adverse effects of long-term proton pump inhibitor therapy","volume":"56","author":"Sheen","year":"2011","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jaip.2019.08.022_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1080\/15563650.2017.1349320","article-title":"Histamine poisoning from insect consumption: an outbreak investigation from Thailand","volume":"56","author":"Chomchai","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"10.1016\/j.jaip.2019.08.022_bib37","first-page":"817","article-title":"Scombroid fish poisoning associated with tuna steaks--Louisiana and Tennessee, 2006","volume":"56","year":"2007","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaip.2019.08.022_bib38","first-page":"297","article-title":"An outbreak of scombroid fish poisoning in a kindergarten","volume":"44","author":"Wu","year":"2003","journal-title":"Acta Paediatr Taiwan"},{"key":"10.1016\/j.jaip.2019.08.022_bib39","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s11606-012-1996-6","article-title":"A case of histamine fish poisoning in a young atopic woman","volume":"27","author":"Wilson","year":"2012","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jaip.2019.08.022_bib40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1442-2026.2003.00448.x","article-title":"Something fishy: six patients with an unusual cause of food poisoning!","volume":"15","author":"Hall","year":"2003","journal-title":"Emerg Med (Fremantle)"},{"key":"10.1016\/j.jaip.2019.08.022_bib41","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1111\/all.13226","article-title":"Validation of international consensus equation for acute serum total tryptase in mast cell activation: a perioperative perspective","volume":"72","author":"Baretto","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.08.022_bib42","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0190-9622(96)90679-9","article-title":"Value of urinary N-methylhistamine measurements in childhood mastocytosis","volume":"35","author":"Van Gysel","year":"1996","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2019.08.022_bib43","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1046\/j.1365-2230.2002.01072.x","article-title":"Urinary N-methylhistamine as an indicator of bone marrow involvement in mastocytosis","volume":"27","author":"Oranje","year":"2002","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaip.2019.08.022_bib44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.cccn.2005.03.041","article-title":"Comparison of serum tryptase and urine N-methylhistamine in patients with suspected mastocytosis","volume":"359","author":"van Toorenenbergen","year":"2005","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jaip.2019.08.022_bib45","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.iac.2018.04.011","article-title":"Mast cell mediators of significance in clinical practice in mastocytosis","volume":"38","author":"Butterfield","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.08.022_bib46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jaip.2014.06.011","article-title":"Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha","volume":"2","author":"Ravi","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.08.022_bib47","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/iid3.94","article-title":"Prostaglandin D2 metabolites as a biomarker of in\u00a0vivo mast cell activation in systemic mastocytosis and rheumatoid arthritis","volume":"4","author":"Cho","year":"2016","journal-title":"Immun Inflamm Dis"},{"key":"10.1016\/j.jaip.2019.08.022_bib48","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4065\/70.5.481","article-title":"Aspirin idiosyncrasy in systemic mast cell disease: a new look at mediator release during aspirin desensitization","volume":"70","author":"Butterfield","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jaip.2019.08.022_bib49","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/all.12668","article-title":"Urinary 11beta-PGF2alpha and N-methyl histamine correlate with bone marrow biopsy findings in mast cell disorders","volume":"70","author":"Divekar","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2019.08.022_bib50","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.prostaglandins.2010.03.003","article-title":"Increased leukotriene E4 excretion in systemic mastocytosis","volume":"92","author":"Butterfield","year":"2010","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"10.1016\/j.jaip.2019.08.022_bib51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2222.2008.03104.x","article-title":"Increased production of cysteinyl leukotrienes and prostaglandin D2 during human anaphylaxis","volume":"39","author":"Ono","year":"2009","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2019.08.022_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1159\/000237133","article-title":"Cysteinyl leukotriene production in anaphylactic reactions","volume":"108","author":"Denzlinger","year":"1995","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1023\/A:1018886423475","article-title":"Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls","volume":"42","author":"Bischoff","year":"1997","journal-title":"Dig Dis Sci"},{"issue":"Suppl 1","key":"10.1016\/j.jaip.2019.08.022_bib54","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/PL00000171","article-title":"Methylhistamine in Crohn's disease (CD): increased production and elevated urine excretion correlates with disease activity","volume":"49","author":"Weidenhiller","year":"2000","journal-title":"Inflamm Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib55","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1111\/j.1572-0241.2002.07028.x","article-title":"Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease","volume":"97","author":"Winterkamp","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jaip.2019.08.022_bib56","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.08.022_bib57","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0190-9622(08)81953-6","article-title":"Interferon treatment of patients with chronic urticaria and mastocytosis","volume":"30","author":"Czarnetzki","year":"1994","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.jaip.2019.08.022_bib58","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1365-2257.1994.tb00423.x","article-title":"Systemic mastocytosis\u2014a case treated with interferon alpha and radiotherapy","volume":"16","author":"Harrison","year":"1994","journal-title":"Clin Lab Haematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/ajh.2830470121","article-title":"Long-term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia","volume":"47","author":"Pulik","year":"1994","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib60","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1365-2796.1997.tb00013.x","article-title":"Clinical stable systemic mastocytosis with interferon alpha-2b therapy","volume":"241","author":"Hubner","year":"1997","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jaip.2019.08.022_bib61","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2019.08.022_bib62","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib63","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.patbio.2004.04.012","article-title":"Interest of interferon alpha in systemic mastocytosis. The French experience and review of the literature","volume":"52","author":"Simon","year":"2004","journal-title":"Pathol Biol (Paris)"},{"key":"10.1016\/j.jaip.2019.08.022_bib64","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2169\/internalmedicine.48.2294","article-title":"Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha","volume":"48","author":"Yoshida","year":"2009","journal-title":"Intern Med"},{"key":"10.1016\/j.jaip.2019.08.022_bib65","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2174\/138945011794815293","article-title":"Interferon-alpha treatment in systemic mastocytosis","volume":"12","author":"Bjerrum","year":"2011","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.jaip.2019.08.022_bib66","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/ajh.21561","article-title":"Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine","volume":"84","author":"Lim","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib67","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib68","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2298\/VSP1105444R","article-title":"Response to cladribine in patient with systemic mastocytosis","volume":"68","author":"Radojkovic","year":"2011","journal-title":"Vojnosanit Pregl"},{"key":"10.1016\/j.jaip.2019.08.022_bib69","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/bjh.12156","article-title":"Response of urticaria pigmentosa to cladribine in a patient with systemic mastocytosis","volume":"160","author":"Bennett","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib70","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2015-06-649525","article-title":"Cladribine for mastocytosis: benefits and risks","volume":"126","author":"Akin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib71","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib72","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1056\/NEJMc1515403","article-title":"Midostaurin in advanced systemic mastocytosis","volume":"374","author":"Chandesris","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.08.022_bib73","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2019.08.022_bib74","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood-2017-05-781237","article-title":"A\u00a0molecular roadmap for midostaurin in mastocytosis","volume":"130","author":"Gotlib","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood-2017-01-764423","article-title":"Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers","volume":"130","author":"Jawhar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib76","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/leu.2017.234","article-title":"Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial","volume":"32","author":"DeAngelo","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2019.08.022_bib77","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1634\/theoncologist.2018-0222","article-title":"FDA approval summary: midostaurin for the treatment of advanced systemic mastocytosis","volume":"23","author":"Kasamon","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaip.2019.08.022_bib78","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: an open-label phase 2 trial","volume":"142","author":"van Anrooij","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib79","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1111\/bjh.15980","article-title":"Aggressive systemic mastocytosis: midostaurin is safe, feasible and associated with durable response post-haploidentical allogeneic stem cell transplant","volume":"186","author":"Martynova","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib80","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-NB2017-177","article-title":"Rapid responses to avapritinib (BLU-285) in mastocytosis","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaip.2019.08.022_bib81","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1158\/1078-0432.CCR-18-1858","article-title":"Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors","volume":"25","author":"Gebreyohannes","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib82","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/s41375-019-0450-8","article-title":"Inhibitory effects of midostaurin and avapritinib on myeloid progenitors derived from patients with KIT D816V positive advanced systemic mastocytosis","volume":"33","author":"Lubke","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jaip.2019.08.022_bib83","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1021\/acs.molpharmaceut.9b00274","article-title":"Avapritinib, a selective inhibitor of KIT and PDGFRalpha reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines","volume":"16","author":"Wu","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.jaip.2019.08.022_bib84","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib85","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.leukres.2003.09.001","article-title":"Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis","volume":"28","author":"Musto","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib86","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.jaip.2019.08.022_bib87","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A\u00a0novel K509I mutation of KIT identified in familial mastocytosis-in\u00a0vitro and in\u00a0vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib88","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.20833","article-title":"Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation","volume":"82","author":"Dalal","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib89","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1600-0609.2007.00905.x","article-title":"Systemic mastocytosis: documented pathologic response to imatinib","volume":"79","author":"Gollard","year":"2007","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib90","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/labinvest.3700524","article-title":"Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation","volume":"87","author":"Nakagomi","year":"2007","journal-title":"Lab Invest"},{"key":"10.1016\/j.jaip.2019.08.022_bib91","first-page":"93","article-title":"Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT","volume":"4","author":"Valent","year":"2014","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib92","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: a phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Alvarez-Twose","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jaip.2019.08.022_bib93","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.leukres.2018.12.010","article-title":"Molecular response to imatinib in KIT F522C-mutated systemic mastocytosis","volume":"77","author":"Broderick","year":"2019","journal-title":"Leuk Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib94","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib95","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","article-title":"KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib","volume":"118","author":"Gleixner","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaip.2019.08.022_bib96","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MAJ.0b013e31821d41dd","article-title":"Polycythemia from mast cell activation syndrome: lessons learned","volume":"342","author":"Afrin","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaip.2019.08.022_bib97","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.tripleo.2010.11.030","article-title":"Burning mouth syndrome and mast cell activation disorder","volume":"111","author":"Afrin","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.jaip.2019.08.022_bib98","doi-asserted-by":"crossref","first-page":"113","DOI":"10.7205\/MILMED-D-11-00111","article-title":"Mast cell activation syndrome masquerading as agranulocytosis","volume":"177","author":"Afrin","year":"2012","journal-title":"Mil Med"},{"key":"10.1016\/j.jaip.2019.08.022_bib99","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.prp.2011.12.005","article-title":"Sclerosing mediastinitis and mast cell activation syndrome","volume":"208","author":"Afrin","year":"2012","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.jaip.2019.08.022_bib100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/2162-3619-2-28","article-title":"Utility of hydroxyurea in mast cell activation syndrome","volume":"2","author":"Afrin","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.jaip.2019.08.022_bib101","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MAJ.0000000000000325","article-title":"Mast cell activation syndrome as a significant comorbidity in sickle cell disease","volume":"348","author":"Afrin","year":"2014","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jaip.2019.08.022_bib102","first-page":"129","article-title":"Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome","volume":"28","author":"Afrin","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jaip.2019.08.022_bib103","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/ejh.12606","article-title":"Successful treatment of mast cell activation syndrome with sunitinib","volume":"95","author":"Afrin","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib104","doi-asserted-by":"crossref","first-page":"E74","DOI":"10.1002\/ajh.23942","article-title":"Bosutinib, a Lyn\/Btk inhibiting tyrosine kinase inhibitor, is ineffective in advanced systemic mastocytosis","volume":"90","author":"Randall","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib105","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.12893","article-title":"Successful targeted treatment of mast cell activation syndrome with tofacitinib","volume":"99","author":"Afrin","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jaip.2019.08.022_bib106","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(16)31403-9","article-title":"Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: a randomised, placebo-controlled, phase 3 study","volume":"389","author":"Lortholary","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2019.08.022_bib107","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.12688\/f1000research.13343.1","article-title":"Case report: treatment of systemic mastocytosis with sunitinib","volume":"6","author":"Molderings","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib108","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.12688\/f1000research.12730.1","article-title":"Risk of solid cancer in patients with mast cell activation syndrome: results from Germany and USA","volume":"6","author":"Molderings","year":"2017","journal-title":"F1000Res"},{"key":"10.1016\/j.jaip.2019.08.022_bib109","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41398-018-0143-5","article-title":"White matter abnormalities are also repeatedly present in patients with systemic mast cell activation syndrome","volume":"8","author":"Haenisch","year":"2018","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.jaip.2019.08.022_bib110","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.clbc.2017.12.004","article-title":"Mast cell activation syndrome mimicking breast cancer: case report with pathophysiologic considerations","volume":"18","author":"Molderings","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.jaip.2019.08.022_bib111","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00251-017-0981-y","article-title":"Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing","volume":"69","author":"Altmuller","year":"2017","journal-title":"Immunogenetics"},{"key":"10.1016\/j.jaip.2019.08.022_bib112","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13256-017-1278-3","article-title":"Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report","volume":"11","author":"Malik","year":"2017","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.jaip.2019.08.022_bib113","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaip.2018.07.032","article-title":"The mastocytosis society survey on mast cell disorders: part 2\u2014patient clinical experiences and beyond","volume":"7","author":"Russell","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.08.022_bib114","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2019.08.022_bib115","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1161\/01.HYP.0000158259.68614.40","article-title":"Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders","volume":"45","author":"Shibao","year":"2005","journal-title":"Hypertension"},{"key":"10.1016\/j.jaip.2019.08.022_bib116","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.iac.2018.04.004","article-title":"Association of postural tachycardia syndrome and Ehlers-Danlos syndrome with mast cell activation disorders","volume":"38","author":"Bonamichi-Santos","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.08.022_bib117","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.autneu.2018.05.001","article-title":"Postural orthostatic tachycardia syndrome and the potential role of mast cell activation","volume":"215","author":"Doherty","year":"2018","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.jaip.2019.08.022_bib118","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejmg.2017.10.005","article-title":"A\u00a0classical Ehlers-Danlos syndrome family with incomplete presentation diagnosed by molecular testing","volume":"61","author":"Colombi","year":"2018","journal-title":"Eur J Med Genet"},{"key":"10.1016\/j.jaip.2019.08.022_bib119","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.autneu.2018.02.006","article-title":"Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome","volume":"215","author":"Roma","year":"2018","journal-title":"Auton Neurosci"},{"key":"10.1016\/j.jaip.2019.08.022_bib120","first-page":"162","article-title":"A\u00a0review of the dermatologic symptoms of idiopathic mast cell activation syndrome","volume":"18","author":"Qureshi","year":"2019","journal-title":"J\u00a0Drugs Dermatol"},{"key":"10.1016\/j.jaip.2019.08.022_bib121","first-page":"1","article-title":"The relationship between hypermobile Ehlers-Danlos syndrome (hEDS), postural orthostatic tachycardia syndrome (POTS), and mast cell activation syndrome (MCAS)","author":"Kohn","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib122","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.jaci.2013.11.039","article-title":"Mendelian inheritance of elevated serum tryptase associated with atopy and connective tissue abnormalities","volume":"133","author":"Lyons","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib123","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jaip.2019.08.022_bib124","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary alpha tryptasemia: genotyping and associated clinical features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.jaip.2019.08.022_bib125","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1172\/JCI118337","article-title":"The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis","volume":"96","author":"Schwartz","year":"1995","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jaip.2019.08.022_bib126","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S0091-6749(99)70184-3","article-title":"The potential clinical utility of serum alpha-protryptase levels","volume":"103","author":"Kanthawatana","year":"1999","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib127","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2007.02.007","article-title":"Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levels","volume":"123","author":"Akin","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib128","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jaci.2014.06.007","article-title":"Familial hypertryptasemia with associated mast cell activation syndrome","volume":"134","author":"Sabato","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2019.08.022_bib129","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/gim.2017.136","article-title":"A\u00a0common haplotype containing functional CACNA1H variants is frequently coinherited with increased TPSAB1 copy number","volume":"20","author":"Lyons","year":"2018","journal-title":"Genet Med"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819307299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219819307299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:21:04Z","timestamp":1761974464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219819307299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":129,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2213219819307299"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2019.08.022","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mast Cell Activation Syndrome: Tools for Diagnosis and Differential Diagnosis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2019.08.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}